Combination Therapy With Ruxolitinib and Ibrutinib Reduces the Severity of Murine Sclerodermatous Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation (SOHO 2026) - Sep 1, 2026 - Abstract #CT-1066; Location: LEVEL 3, HALL B3; "Our results suggest that combination therapy with ruxolitinib and ibrutinib ameliorates sclerodermatous cGVHD. Future studies incorporating gene expression profiling using RNA-seq and targeted gene analyses, as well as protein-level validation, will elucidate the molecular mechanisms mediating the effects of this combination treatment in sclerodermatous cGVHD. BTK: Bruton tyrosine kinase, CXCL10: C-X-C motif chemokine ligand 10, JAK: Janus kinase, RNA-seq: RNA sequencing, STAT: signal transducer and activator of transcription."
Combination therapy • Preclinical • Oncology • CXCL10
|
|
Vasantharaja Raguraman PhD 1; Shanid Mohiyuddin PhD 1; Sahra Gabure 1; Nashwan Jabbour MD 2; Melissa Kesler MD 2; Senthilnathan Palaniyandi PhD 1; Gerhard Hildebrandt MD,FACP 1
|